BD² opens third funding round, offering clinic sites up to $2.35M to join bipolar research network
What's the deal? BD²Dealroom has a profile for this one. Try Dealroom → (Breakthrough Discoveries for thriving with Bipolar Disorder) has opened a third call for clinical sites to join its Integrated Network, offering selected sites up to $2.35 million each over five years. The nonprofit is now accepting applications from organizations in the US, Canada, and the UK.
What does BD² do? It is an independent nonprofit that funds and advances research and care for bipolar disorder. Its Integrated Network pairs a longitudinal cohort study with a learning health network aimed at improving care outcomes.
Where it stands: The network currently spans 11 clinical institutions across the US and Canada. This expansion widens eligibility to the UK for the first time and opens applications to public, private, non-profit, and for-profit organizations providing clinical care for people with bipolar disorder.
Why now? In March 2026, the network released its first dataset — combining clinical, biological, neuroimaging, and behavioral data from 615 participants across its initial six sites. BD² called it the most comprehensive multimodal dataset ever created for a psychiatric condition, and adding sites means more longitudinal data.
What's the endgame? New sites will contribute to both parts of the network, feeding data into the science while improving day-to-day care. "Every new site brings us closer to the scale and the diversity we need — not just to advance the science, but to make sure that translates into better care for people with bipolar disorder," said Emily Baxi, director of clinical transformation at BD².
The timeline: Applications are due January 15, 2027, with awardees notified in May 2027 and an expected start date of June 2027.
The signal: By expanding across borders and funding both research and care under one network, BD² is building the kind of large, shared dataset that psychiatry has long lacked — betting that scale and open data can shorten the path from discovery to better treatment.
Read more: business.theantlersamerican.com
Image credit: Generated with Gemini
